BioSpace News Archive

Ascentage Pharma announced that it has released updated data of its novel drug candidate AGP-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor, in patients with non-small-cell lung cancer in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.

Innovent Biologics, Inc. announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor, were published in the Journal of Clinical Oncology and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting.

Detailed positive results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard of care chemotherapy in patients with HR positive, HER2 low metastatic breast cancer and the overall trial population following one or more lines of endocrine therapy.

Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population following one or more lines of endocrine therapy.

Tolmar Inc., a fully integrated pharmaceutical company, announced results from a landmark survey of more than 300 US physicians, revealing barriers to treatment with testosterone-replacement therapy among patients and physicians that, if addressed, may improve patient care.

NANOBIOTIX announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors as a second-or-later line therapy for patients with advanced solid and metastatic tumors.

Flamingo Therapeutics announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology taking place in Chicago, Illinois.

Seer, Inc. announced that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to date utilizing the Seer Proteograph™ Product Suite and Thermo Fisher Scientific’s Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer.

Telix Pharmaceuticals Limited announces that it has completed the submission of a Biologics License Application to the United States Food and Drug Administration for its investigational radiodiagnostic PET1 agent, TLX250-CDx, for the characterisation of renal masses as clear cell renal cell carcinoma.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002.